http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
-
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
-
Freeline to Present at 2023 Jefferies Healthcare Conference
-
Freeline Reports First Quarter 2023 Financial Results and Business Highlights
-
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease
-
Freeline Therapeutics Holdings (FRLN) Announces ADS Ratio Change to 1:15
-
Freeline Completes ADS Ratio Change
-
Freeline Therapeutics Holdings (FRLN) Announces Proposed ADS Ratio Change
-
Freeline Announces Proposed ADS Ratio Change
-
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
-
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
-
Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary
-
Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
-
World Hemophilia Day 2022 - "Access for All: Partnership. Policy. Progress. Engaging your government, integrating inherited bleeding disorders into national policy"
-
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
-
PureTech Health plc – Half-Year Report
-
PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer
-
Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board
-
Citi Appointed as Depositary Bank for Freeline’s ADR Programme

